FDA-filed SPL labeling · retrieved through openFDA

Docetaxel

Docetaxel is a chemotherapy medicine used intravenously to treat breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck.

Brand names DocivyxBeizray
Drug class ⓘ Microtubule Inhibitor
Rx Form 1 Route Intravenous
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 32 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveDec 15, 2025
Clinical labels in scope ⓘ32
AvailabilityRx
Earliest approval/marketing year ⓘ1996
FDA-listed product records ⓘ176
Boxed warningYes
How we combine label and product data →
Other forms & routes:
Injection
⭐ Docetaxel at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Docetaxel is a powerful intravenous chemotherapy used to treat several advanced or metastatic cancers, including breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. It requires careful monitoring of blood counts and liver function before every cycle, and serious risks — including life-threatening infections and allergic reactions — mean it is always given in a specialized clinical setting. Follow your care team's instructions closely, report any fever or unusual symptoms immediately, and never miss a pre-treatment blood test.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Docetaxel carries a serious FDA Boxed Warning — the highest-level safety alert. The risk of treatment-related death is higher in patients with abnormal liver function, those receiving higher doses, and patients with non-small cell lung cancer who have had prior platinum-based chemotherapy. Docetaxel must not be given to patients with elevated bilirubin or certain combinations of elevated liver enzymes, because these patients face a much greater risk of severe complications including life-threatening low white blood cell counts, serious infections, severe mouth sores, skin toxicity, and death. Liver function tests must be checked before every treatment cycle. Treatment must not begin if neutrophil (white blood cell) counts are too low. Severe fluid retention can occur and requires monitoring. Serious allergic reactions, including anaphylaxis (a sudden, severe whole-body allergic reaction), have been reported and can be fatal. All patients must receive corticosteroid pre-medication before each infusion to reduce these risks.

Read the full warning on DailyMed →

📖 Docetaxel: Patient Information Guide

A plain-language walkthrough of Docetaxel — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for▾

Docetaxel injection is approved to treat several types of cancer, sometimes alone and sometimes in combination with other chemotherapy drugs.

  • Breast cancer: Used as a single agent for locally advanced or metastatic breast cancer after prior chemotherapy has failed. Also used in combination with doxorubicin and cyclophosphamide as adjuvant (post-surgery) treatment for operable breast cancer that has spread to lymph nodes.
  • Non-small cell lung cancer (NSCLC): Used as a single agent after platinum-based chemotherapy has failed. Also used with cisplatin as first-line treatment for unresectable, locally advanced, or metastatic NSCLC in patients who haven't had prior chemotherapy for this condition.
  • Castration-resistant prostate cancer: Used in combination with prednisone for metastatic castration-resistant prostate cancer (cancer that has spread and is no longer responding to hormone therapy).
  • Gastric adenocarcinoma (stomach cancer): Used with cisplatin and fluorouracil for advanced gastric adenocarcinoma — including cancer of the gastroesophageal junction — in patients who haven't had prior chemotherapy for advanced disease.
  • Squamous cell carcinoma of the head and neck: Used with cisplatin and fluorouracil as induction treatment (given before other treatments) for locally advanced disease.
⚙️How it works▾

Docetaxel is a microtubule inhibitor — it targets the internal scaffolding that cancer cells depend on to divide. Normally, cells build and dismantle these tiny structural fibers (microtubules) in a carefully timed cycle when they split into two. Docetaxel locks those fibers in place so they can't break down, which jams the cell division process and ultimately causes cancer cells to die.

What sets docetaxel apart from some other drugs in its class is that it doesn't change the structure of the microtubule fibers it binds to — it simply prevents them from functioning and disassembling normally, making it a uniquely effective cell-division blocker.

💊How it's taken▾

Docetaxel is always given as an intravenous (IV) infusion — directly into a vein — at a specialized clinic or hospital. Infusions typically run over about 1 hour and are given once every 3 weeks. Before each infusion, patients take an oral corticosteroid (a steroid by mouth) to reduce the risk of fluid buildup and allergic reactions.

  • The exact dose depends on which cancer is being treated, your body size, and whether docetaxel is given alone or with other drugs.
  • Doses may be adjusted or delayed based on blood counts, liver function, and how your body tolerates treatment.
  • Always follow your oncology team's specific instructions — never adjust your schedule on your own.
🤒Side effects — in detail▾

Docetaxel can cause a wide range of side effects. The most common ones include:

  • Infections (because of low white blood cell counts)
  • Neutropenia — dangerously low infection-fighting white blood cells
  • Anemia (low red blood cells, causing fatigue)
  • Febrile neutropenia — fever combined with very low white blood cells (a medical emergency)
  • Nausea, vomiting, diarrhea, and mouth sores (mucositis)
  • Hair loss (alopecia)
  • Fatigue and weakness (asthenia)
  • Fluid retention and swelling
  • Nail changes and skin reactions
  • Numbness or tingling in hands and feet (peripheral neuropathy)
  • Changes in taste (dysgeusia)

Serious reactions requiring immediate medical attention include severe allergic reactions, life-threatening infections, severe skin blistering or peeling, vision changes (cystoid macular edema), and signs of colitis or bowel inflammation. Tell your care team immediately if any of these occur.

⚠️Warnings & precautions▾

The most critical risks with docetaxel are serious enough to carry an FDA Boxed Warning — the strongest safety alert available. Risk of death is significantly increased in patients with abnormal liver function, those receiving higher doses, and those with prior platinum-based chemotherapy for lung cancer. Severe drops in white blood cells (neutropenia) can lead to fatal infections and sepsis. Blood counts and liver function tests must be checked before every treatment cycle.

  • Severe allergic reactions (hypersensitivity): Can be life-threatening; all patients must receive corticosteroid pre-medication before each infusion.
  • Fluid retention: Significant swelling can build up over multiple cycles; monitoring is essential.
  • Liver toxicity: Docetaxel must not be given to patients with certain elevated liver lab values.
  • Skin reactions: Severe redness, swelling, or peeling of the skin may require stopping treatment.
  • Nerve damage (neuropathy): Numbness, pain, or tingling may worsen with continued treatment.
  • Eye problems: Cystoid macular edema (swelling in the eye) has been reported and requires treatment discontinuation.
  • Second cancers: Patients treated with docetaxel-containing regimens should be monitored for delayed development of secondary malignancies.
  • Alcohol content: Docetaxel injection contains alcohol, which may impair driving or operating machinery immediately after infusion.
  • Embryo-fetal toxicity: Docetaxel can cause serious harm to an unborn baby.
🔀What it interacts with▾

Docetaxel is broken down by a liver enzyme called CYP3A4, so drugs that affect this enzyme can significantly change how much docetaxel is in your blood.

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, certain HIV protease inhibitors like ritonavir): These slow down docetaxel's breakdown, raising drug levels and increasing toxicity risk — avoid combining when possible.
  • CYP3A4 inducers (drugs that speed up the CYP3A4 enzyme): These can lower docetaxel levels, potentially making it less effective.
  • Other CYP3A4 substrates (drugs also processed by the same enzyme): Competition for metabolism may alter the effects of docetaxel or the other drug.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it▾
  • Abnormal liver function: Docetaxel must not be given if bilirubin exceeds the upper limit of normal, or if certain combinations of liver enzymes are elevated — your team will check these labs before every cycle.
  • Low blood counts: Treatment cannot start or restart if neutrophil (white blood cell) counts are too low.
  • Severe hypersensitivity: Patients with a known serious allergy to docetaxel or polysorbate 80 should not receive it.
  • Pregnancy: Docetaxel can cause fetal harm. Pregnancy must be ruled out before starting, and effective contraception is required during treatment — for 2 months after the last dose for women, and 4 months for men.
  • Breastfeeding: Do not breastfeed during treatment or for 1 week after the last dose.
  • Male fertility: Docetaxel may impair fertility in men; discuss this with your doctor before treatment if this is a concern.
  • Older adults: Patients 65 and older may experience more frequent or severe side effects such as diarrhea, infections, edema, and fatigue — close monitoring is important.
  • Children: Efficacy has not been established in pediatric patients; the alcohol content of the injection must also be considered in this age group.
  • Driving and machinery: The alcohol content in docetaxel injection may impair your ability to drive or use machines immediately after infusion.
🚑If you take too much▾

There is no antidote for a docetaxel overdose. If too much is given, the main risks are severe suppression of bone marrow (leading to dangerously low blood counts), nerve damage, and painful mouth sores. Patients would need to be monitored closely in a specialized setting, with prompt treatment using G-CSF (a medication that helps the body make more white blood cells) and supportive care. Two reported overdose cases resulted in severe neutropenia and other side effects, but both patients recovered.

📡Pharmacodynamics — effects in the body▾

The precise relationship between docetaxel blood levels and its effects on tumors — and how quickly those effects develop — has not been fully characterized. What is known is that docetaxel disrupts the cell division machinery in cancer cells, preventing them from multiplying. Its impact on blood cell counts (particularly white blood cells) is one measurable effect that guides dosing decisions in clinical practice.

🔬Pharmacokinetics — how your body processes it▾

After an IV infusion, docetaxel distributes rapidly and widely throughout the body, with an average distribution volume of about 113 liters. It is about 94–97% bound to proteins in the blood. The drug is broken down mainly by the CYP3A4 enzyme in the liver and eliminated primarily through the feces (about 75% within 7 days), with a small amount leaving through the urine. The terminal half-life — how long it takes the body to clear half the remaining drug — averages about 116 hours (roughly 5 days), meaning the drug stays in the body for an extended period after each infusion. Liver impairment can significantly slow clearance, raising drug exposure by roughly 38% in patients with certain liver abnormalities.

📦How to store it▾

Store at 20º to 25°C (68º to 77°F) . protect from light. stored between 2° and 8°C (36° and 46°F) and protected from light.

📄 Written from Docetaxel’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Docetaxel — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is docetaxel being used to treat me for? ▾
Docetaxel is a chemotherapy drug used for several types of cancer — most commonly breast cancer, non-small cell lung cancer, prostate cancer that no longer responds to hormone therapy, stomach (gastric) cancer, and head and neck cancer. Which one it's targeting for you depends on what your oncologist prescribed it for. It's used either on its own or alongside other chemo drugs depending on your situation.
How will I receive my docetaxel treatment, and how often? ▾
You'll get docetaxel as an IV infusion — a drip into a vein — that takes about one hour. Treatments are usually given once every three weeks at your cancer center or hospital. Before each infusion, you'll take a steroid by mouth (usually starting the day before) to lower the risk of swelling and allergic reactions. Your team will schedule everything and adjust it as needed based on your blood tests and how you're feeling.
What side effects should I realistically expect? ▾
The most common ones are hair loss, fatigue, nausea, diarrhea, mouth sores, and swelling in the legs. Your blood counts will drop — especially your white blood cells — which makes infection a real concern. Nail changes and skin reactions are also common. Most of these are manageable with your care team's support, but you should always report a fever right away, since a fever with low white blood cell counts is a medical emergency that needs immediate treatment.
When should I call my doctor or go to the emergency room after an infusion? ▾
Call your care team right away — or go to the ER — if you develop a fever (even a mild one), chills, or signs of infection, since your immune system is weakened during treatment. Also seek immediate help for signs of a severe allergic reaction (difficulty breathing, chest tightness, hives), significant shortness of breath or sudden swelling, severe skin blistering or peeling, unusual bleeding or bruising, and any new or worsening vision changes or severe abdominal pain.
Are there any medications or supplements I need to avoid while on docetaxel? ▾
Yes — some drugs can interfere with how your body processes docetaxel. Certain antifungal medications like ketoconazole and some HIV medicines (such as ritonavir) can raise docetaxel levels in your blood to dangerous amounts. It's really important to give your oncologist and pharmacist a full list of everything you take — including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements — before you start treatment.
Can I get pregnant or father a child while taking docetaxel? ▾
No — this is very important. Docetaxel can cause serious harm to an unborn baby. If you could become pregnant, you need to use reliable birth control during treatment and for at least 2 months after your last dose. If you're a man, you should use contraception for 4 months after your last dose. Your care team will check for pregnancy before starting treatment. You also should not breastfeed during treatment or for one week after your last dose.
Is Docetaxel available over the counter? ▾
Docetaxel is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.
When was Docetaxel first available? ▾
Docetaxel has been available in the United States since at least 1996, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Docetaxel? ▾
Docetaxel is supplied by 42 manufacturers listed in the FDA NDC Directory, including Hospira, Inc., Mylan Institutional LLC, Baxter Healthcare Corporation.

💬 Answers drafted from Docetaxel’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

🌿Drug & Supplement CheckerDocetaxel vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Docetaxel NDCs & costs 🅰️Browse Drugs A–ZLook up any medication

💊 How Docetaxel comes

Docetaxel is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

By injection · Into a vein
Brands Beizray Docivyx
How this form is used
What it may be used for
  • Beizray, Docetaxel, Docetaxel anhydrous, and Docivyx injections are each indicated for locally advanced or metastatic breast cancer after prior chemotherapy failure, and for adjuvant treatment of operable node-positive breast cancer in combination with doxorubicin and cyclophosphamide
  • Beizray, Docetaxel, Docetaxel anhydrous, and Docivyx injections are each indicated for locally advanced or metastatic non-small cell lung cancer — either after platinum therapy failure (single agent) or with cisplatin as first-line therapy
  • Beizray, Docetaxel, Docetaxel anhydrous, and Docivyx injections are each indicated for metastatic castration-resistant prostate cancer in combination with prednisone
  • Beizray, Docetaxel, Docetaxel anhydrous, and Docivyx injections are each indicated for advanced gastric adenocarcinoma and for locally advanced squamous cell carcinoma of the head and neck, both in combination with cisplatin and fluorouracil
Important instructions
  • All docetaxel injection products are given intravenously over 1 hour, typically once every 3 weeks, in a clinical facility equipped to manage serious reactions such as anaphylaxis
  • All patients must receive pre-medication with an oral corticosteroid before each infusion to reduce the risk of fluid retention and hypersensitivity reactions
  • Beizray should not be substituted for other docetaxel products without specific guidance — it is not interchangeable on a product-to-product basis
  • Docetaxel anhydrous and Docivyx labels specify that PVC (polyvinyl chloride) equipment is not recommended and that only a 21-gauge needle should be used to withdraw the product from the vial
Available strengths 9 strengths
10 mg/mL 20 mg/2 mL 20 mg/mL 80 mg/4 mL 80 mg/8 mL 100 mg/100 mg
Show 3 more strengths Show fewer strengths
160 mg/8 mL 160 mg/16 mL 1 g/g
159 FDA-listed product records ⓘ

📊 Docetaxel across the U.S. market

How Docetaxel appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1
Dose forms ⓘ
42
Manufacturers
4
Brand names
176
FDA-listed product records ⓘ
1996
First marketed ⓘ

Also listed with the FDA, not a patient dose form: Powder (15) · Kit (2) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Hospira, Inc.19%
Mylan Institutional LLC10%
Baxter Healthcare Corporation7%
Amneal Pharmaceuticals LLC5%
Jiangsu Hengrui Pharmaceuticals Co., Ltd.4%
Actavis Pharma, Inc.3%
Other makers52%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Docetaxel is used

A general measure of how commonly Docetaxel is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Docetaxel is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

13,978
Medicaid prescriptions filled (Q1–Q4 2025)
$13.3M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Docetaxel prescribed? Of the 1,596 medications we measure, Docetaxel ranks #870 by Medicaid prescriptions — more than 45% of them.

Where Docetaxel ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #870 of 1,596
#865 Etelcalcetide Injectio... 14,185 Rx #866 Azacitidine Injection 14,177 Rx #867 Cevimeline 14,121 Rx #868 Natalizumab Injection 14,035 Rx #869 Formoterol Oral Inhala... 14,034 Rx #870 Docetaxel Injection 13,978 Rx #871 Docetaxel 13,978 Rx #872 Pertuzumab Injection 13,810 Rx #873 Formoterol / Glycopyrr... 13,780 Rx #874 Sodium Picosulfate, Ma... 13,778 Rx #875 Latanoprostene Bunod O... 13,742 Rx

Utilization by Docetaxel product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 10 mg/mL injectable solution is the most-dispensed Docetaxel product — about 41% of these Medicaid prescriptions.

docetaxel 10 MG/ML Injectable Solution Most dispensed

5,777 Medicaid prescriptions (Q1–Q4 2025) 41% of Docetaxel prescriptions shown $1.4M gross reimbursement (before rebates) ≈ $242 per prescription (gross)

Summed across the 14 of 41 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1093280

docetaxel 20 MG/ML Injectable Solution

2,179 Medicaid prescriptions (Q1–Q4 2025) 16% of Docetaxel prescriptions shown $1.1M gross reimbursement (before rebates) ≈ $519 per prescription (gross)

Summed across the 6 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1001405

1 ML docetaxel 20 MG/ML Injection

1,737 Medicaid prescriptions (Q1–Q4 2025) 12% of Docetaxel prescriptions shown $599,159 gross reimbursement (before rebates) ≈ $345 per prescription (gross)

Summed across the 6 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1860480

4 ML docetaxel 20 MG/ML Injection

1,636 Medicaid prescriptions (Q1–Q4 2025) 12% of Docetaxel prescriptions shown $314,696 gross reimbursement (before rebates) ≈ $192 per prescription (gross)

Summed across the 6 of 16 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1860485

8 ML docetaxel 10 MG/ML Injection

1,167 Medicaid prescriptions (Q1–Q4 2025) 8% of Docetaxel prescriptions shown $4.6M gross reimbursement (before rebates) ≈ $3,983 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2679787

2 ML docetaxel 10 MG/ML Injection

780 Medicaid prescriptions (Q1–Q4 2025) 6% of Docetaxel prescriptions shown $2.5M gross reimbursement (before rebates) ≈ $3,154 per prescription (gross)

Summed across the 4 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1860619

16 ML docetaxel 10 MG/ML Injection

500 Medicaid prescriptions (Q1–Q4 2025) 4% of Docetaxel prescriptions shown $2.7M gross reimbursement (before rebates) ≈ $5,374 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2679779

8 ML docetaxel 20 MG/ML Injection

202 Medicaid prescriptions (Q1–Q4 2025) 1% of Docetaxel prescriptions shown $18,661 gross reimbursement (before rebates) ≈ $92 per prescription (gross)

Summed across the 2 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1861411

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Docetaxel, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 40 of 106 listed Docetaxel NDCs with Medicaid activity.

🔍 Compare Docetaxel products

A representative set of FDA-listed product records for Docetaxel — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 176 of 176 products — FDA National Drug Code Directory. See every product, package size and price: browse all 176 Docetaxel NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Docetaxel RxCUI 72962 2 dose forms · 8 strengths
  1. Dose form (SCDF) Injectable Solution RxCUI 376888 In current FDA listings
    Clinical drug / strength (SCD) 10 MG/ML RxCUI 1093280 20 MG/ML RxCUI 1001405

Look up RxCUI 72962 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Docivyx Beizray

🏭 Manufacturers & labelers

Hospira, Inc. 33 Mylan Institutional LLC 17 Baxter Healthcare Corporation 12 Amneal Pharmaceuticals LLC 9 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 7 Actavis Pharma, Inc. 6 Gland Pharma Limited 6 Sandoz Inc. 5 Dr. Reddy's Laboratories Inc. 5 Sagent Pharmaceuticals 4 Meitheal Pharmaceuticals Inc 4 Ingenus Pharmaceuticals, LLC 4 ScinoPharm Taiwan Ltd. 4 Zydus Pharmaceuticals USA Inc. 4 Hikma Pharmaceuticals USA Inc. 4 AuroMedics Pharma LLC 3 Accord Healthcare Inc. 3 Sanofi-Aventis U.S. LLC 3 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 3 Armas Pharmaceuticals Inc. 3 Sun Pharmaceutical Industries, Inc. 3 Eugia US LLC 3 Winthrop U.S, a business of sanofi-aventis U.S. LLC 3 Winthrop U.S. 3

…and 16 more on the FDA NDC directory.

RxNorm drug class

Docetaxel belongs to the Microtubule Inhibitor class.

Pharmacologic class Microtubule Inhibitor
Drug family (ATC) Taxanes

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Dec 15, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Docetaxel.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Docetaxel after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
32
NDC products indexed
176
Distinct labelers/manufacturers represented
42
Linked representative label ⓘ
Zhuhai Beihai Biotech Co., Ltd.
Linked label effective
Dec 15, 2025
Composite sections available
24
Linked SPL Set ID
3538b979-8cac-49ed-b8dc-50f73ce38c72
Linked SPL Document ID
45f7d427-0830-1612-e063-6294a90a04d2
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 32 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Zhuhai Beihai Biotech Co., Ltd. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.